Medico Remedies valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023
Price multiples — at each FY-end close
11.55×————
2.11×————
0.67×————
27.16×————
Enterprise multiples
0.74×————
9.98×————
12.08×————
Yield
8.7%————
3.7%————
Reference — adjusted share basis
₹19.22————
₹1.66₹1.58₹1.22₹1.00₹0.87
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

MEDICO₹19.22

Medico Remedies Limited

· Pharma & Health
₹ CrorePeersMEDICAMEQHALEOSLABSAAREYDRUGSNECLIFEALBERTDAVDVALIANTLABNATCAPSUQZIMLABMcap ₹160 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E————11.55
P/B————2.11
P/Sales————0.67
Price to Free Cash Flow————27.16
Enterprise Multiples
EV/Sales————0.74
EV/EBITDA————9.98
EV/EBIT————12.08
Yield
Earnings Yield %————8.66
FCF Yield %————3.68
Reference — adjusted share basis
Price (FY-end close, adj.)————19.22
EPS (adj.)0.871.001.221.581.66
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.